Literature DB >> 33721608

Impact of sterile leukocyturia on outcome of critically ill patients with severe acute kidney injury.

Sílvia Coelho1, Margarida Monteiro2, Joana Santos3, Francisco Correia4, Patrícia Rodrigues4, Matilde Rito4, Paulo Freitas5.   

Abstract

INTRODUCTION: The role of immunological mechanisms on renal regeneration and functional recovery after an episode of Acute Kidney Injury (AKI) is still understudied. We aim to evaluate the impact of sterile leukocyturia on outcomes of critically-ill AKI patients.
METHODS: A retrospective analysis of critically-ill patients with stage ≥2 AKI by KDIGO was performed. Patients with urinary tract infection, previous renal replacement therapy, chronic kidney disease stage >3 and kidney, urinary tract or prostatic cancer were excluded. Sterile leukocyturia was defined as a positive leukocyte esterase value.
RESULTS: 108 patients with stage ≥2 AKI were included, 39.8% of which had sterile leukocyturia. AKI patients with sterile leukocyturia were older, had more cardiovascular disease and a lower baseline renal function (p < 0.05). They had a higher serum creatinine and leukocytosis at admission, were more frequently septic (p < 0.05) and had more persistent AKI by both KDIGO criteria at multivariable analysis (OR 6.130, 95% CI 2.007-18.747).
CONCLUSION: Sterile leukocyturia was associated with different patient baseline and AKI characteristics and more persistent AKI by both KDIGO criteria. Sterile leukocyturia may represent a surrogate marker of renal inflammation during AKI.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Renal recovery; Renal regeneration; Sterile leukocyturia

Year:  2021        PMID: 33721608     DOI: 10.1016/j.jcrc.2021.02.008

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  1 in total

1.  Urinary immune cell phenotype of severe AKI in critically ill patients.

Authors:  Sílvia Coelho; Maria Guadalupe Cabral; Rute Salvador; Cláudia Andrade; Ana Martins; Bruna Correia; Paulo Freitas; Josep Maria Cruzado; António Jacinto
Journal:  Int Urol Nephrol       Date:  2022-01-23       Impact factor: 2.266

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.